Q3 2020 13F Holders as of 9/30/2020
-
Type / Class
-
Equity / Common Stock, par value $0.0001
-
Shares outstanding
-
53M
-
Number of holders
-
158
-
Total 13F shares, excl. options
-
26.6M
-
Shares change
-
+1.51M
-
Total reported value, excl. options
-
$1.88B
-
Value change
-
+$107M
-
Put/Call ratio
-
0.45
-
Number of buys
-
86
-
Number of sells
-
-74
-
Price
-
$70.57
Significant Holders of Cardlytics, Inc. - Common Stock, par value $0.0001 (CDLX) as of Q3 2020
198 filings reported holding CDLX - Cardlytics, Inc. - Common Stock, par value $0.0001 as of Q3 2020.
Cardlytics, Inc. - Common Stock, par value $0.0001 (CDLX) has 158 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 26.6M shares
of 53M outstanding shares and own 50.12% of the company stock.
Largest 10 shareholders include CAS Investment Partners, LLC (4.39M shares), WELLINGTON MANAGEMENT GROUP LLP (2.18M shares), BlackRock Inc. (1.97M shares), VANGUARD GROUP INC (1.33M shares), KPS Global Asset Management UK Ltd (1.1M shares), 683 Capital Management, LLC (1M shares), WELLS FARGO & COMPANY/MN (962K shares), MORGAN STANLEY (863K shares), JPMORGAN CHASE & CO (706K shares), and AMERIPRISE FINANCIAL INC (684K shares).
This table shows the top 158 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.